Impaired dopamine release in Parkinson’s disease
Open accessThe DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.
Abstract
Parkinson’s disease is the second most common neurodegenerative disease and yet the early pathophysiological events of the condition and sequences of dysfunction remain unclear. The loss of dopaminergic neurons and reduced levels of striatal dopamine are descriptions used interchangeably as underlying the motor deficits in Parkinson’s disease. However, decades of research suggest that dopamine release deficits in Parkinson’s disease do not occur only after cell death, but that there is dysfunction or dysregulation of axonal dopamine release before cell loss. Here we review the evidence for dopamine release deficits prior to neurodegeneration in Parkinson’s disease, drawn from a large and emerging range of Parkinson’s disease models, and the mechanisms by which these release deficits occur. The evidence indicates that impaired dopamine release can result from disruption to a diverse range of Parkinson’s disease-associated genetic and molecular disturbances, and can be considered as a potential pathophysiological hallmark of Parkinson’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This lack of dopamine is understood to be the primary cause of many of the movement disorders [127,128].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469 · cited 1×
“1).(2,3) SNpc neurons project to the dorsal striatum form-”
BackgroundMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 2×
“Loss-of-function mutations in parkin are the most common cause of autosomal recessive Parkinson’s.95 Parkin, encoded by the PRKN gene (previously known as PARK2), is an E3 ubiquitin ligase that regulates proteasome-dependent protein degradation and plays a critical role in mitochondrial quality control.”
BackgroundAGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529 · cited 1×
“1).(2,3) SNpc neurons project to the dorsal striatum form-”
BackgroundHereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481 · cited 1×
“PINK1 is a mitochondrial protein kinase in which loss-of-function mutations are the second most frequent known cause of autosomal recessive Parkinson’s disease.(96) This protein regulates the activity of parkin, affects mitochondrial stability and modulates mito-”
BackgroundMutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563 · cited 1×
“Models employing SNpc or intrastriatal PFF injections that take advantage of the connectivity to the SNpc have the advantages that they have been shown to aggregate endogenous α-synuclein, induce progressive DA system neurodegeneration specific to SNpc while sparing the ventral tegmental area and recapitulate Parkinso…”
BackgroundThe Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro
Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., & Südhof, T. C. (2010) · Science · doi:10.1126/science.1195227 · Cited by 1,812
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765 · cited 2×
“TH, the rate-limiting enzyme in DA synthesis, has been shown to have decreased protein levels or decreased activity in models of Parkinson’s disease carrying mutations in LRRK2, SNCA, DJ-1 and PINK1.”
BackgroundMice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Cited by
Items 101–200 of 228
Xie, W., Wu, K., Zhang, L., Feng, X., Yang, S., Jia, S., Li, Y., & Wang, X. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109708 · Cited by 4
Xiao, B., Zhou, S., Cen, R., Bai, Q., Yuan, W., Xiao, X., Feng, J., & Jiang, J. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124152 · Cited by 4
Distinctive characteristics of dopamine neuron release mechanisms: Insights into Parkinson’s Disease
Martino, E. D., Maduro, S., Luchicchi, A., Wilhelmus, M. M. M., & Orefice, N. S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119534 · Cited by 4
Gao, Y., Li, S., Zhang, J., Zhang, Y., Zhao, Y., Zhang, S., Zuo, L., & Yang, G. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s481252 · Cited by 4
Liu, Q., Huang, B., Guiberson, N. G. L., Chen, S., Zhu, D., Ma, G., Ma, X., Crittenden, J. R., Yu, J., Graybiel, A. M., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn5417 · Cited by 4
“…suggesting a compensatory resprouting of the remaining DA axonal processes, a compensatory up-regulation of TH expression or increased DA release from remaining terminals, or the intact projections from the ventral tegmental area diluting the effects of the loss of SNpc DA neurons ( 81 , 82 ).”
Naranjo-Viteri, A. J., Cometto, M. J., Caverzán, M. D., Champarini, L. G., Zunino, M. P., Abburra, R. E., Hereñú, C. B., & Crespo, R. (2025) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2025.100584 · Cited by 4
Lopes, A. R., Silva, R. M., Fatibello‐Filho, O., & Silva, T. A. (2025) · Chemosensors · doi:10.3390/chemosensors13070254 · Cited by 4
Yan, J., Zhang, Q., Ma, X., Xu, G., Gao, C., & Zhao, L. (2025) · Microchimica Acta · doi:10.1007/s00604-025-07519-w · Cited by 4
Hosokawa, M., Iwasaki, Y., Someya, A., & Tanigawa, T. (2025) · Biomedical Reports · doi:10.3892/br.2025.1959 · Cited by 5
“It has previously been reported that low NE and DA concentrations in the midbrain, as well as low concentra‑ tions of their metabolites, such as DOPAC, are associated with poorer locomotor activity (44).”
An anatomical hotspot for striatal dopamine-acetylcholine interactions during reward and movementPreprint
Bouabid, S., Vu, M.-A. T., Noggle, C. A., Vietti‐Michelina, S., Brimblecombe, K. R., Platt, N. J., Zhang, L., Joshi, A., Cragg, S. J., & Howe, M. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.20.700614 · Cited by 4
Self-citationLi, S., Li, M., Li, Y., Liang, S., Ling, L., Wang, H., & Guo, J. (2025) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x25500673 · Cited by 4
Quantitative multi-metabolite imaging of Parkinson’s disease using AI boosted molecular MRI
Shmuely, H., Rivlin, M., & Perlman, O. (2025) · npj Imaging · doi:10.1038/s44303-025-00130-x · Cited by 5
“Parkinson ’ s disease (PD), the second-most-common neurodegenerative disorder,isdrivenbyacascadeofpathologicalprocesses 1 .”
Exploring apoptotic pathways: implications for cancer, inflammation, and neurodegeneration
Hanbashi, A., Safhi, A. Y., Jali, A. M., Alshahi, H. S., Yousif, O. E. A., Sabei, F. Y., & Fatima, I. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11577-5 · Cited by 3
Liu, X., Li, W., liu, C., Wu, Z., & Li, Y. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.03.041 · Cited by 5
Kempuraj, D., Shi, H., Truong, T. D., Kong, D., Sharma, A., Babu, P. R. R., Belur, M. G., Kothuru, S. P., Chinnappan, B., Pena, C., et al. (2026) · The Neuroscientist · doi:10.1177/10738584261453915 · Cited by 3
“The dopaminergic neuronal loss in the substantia nigra is a major hallmark of PD (Cramb et al 2023; Thangavel et al 2024).”
Impaired Striatum Dopamine Release in Parkinson’s Disease
Adam, H., Gopinath, S. C. B., Adam, T., Salim, E. T., & Fakhri, M. A. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673356301250130074521 · Cited by 3
CCR5 as a key modulator in neurocognitive disorders
Aung, C. T. Z., Abuaqel, K., & Zhou, M. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115450 · Cited by 3
Chen, H., Xie, W., Chang, Z., Zhang, J., & Xie, D. (2024) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2024.127430 · Cited by 3
Li, J., Zhang, S., Du, G., Li, R., He, H., & Guo, Q. (2024) · Materials Letters · doi:10.1016/j.matlet.2024.136603 · Cited by 3
Drug repurposing for neurodegenerative diseases
Shukla, H., John, D., Banerjee, S., & Tiwari, A. K. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.035 · Cited by 3
Fernandes, T. A. A., Tourville, A., Ciss, I., Silva, R. R., de Mattos, B. A., Pereira, M. D. S., Oblaza, M., Brunel, J. M., Ferrié, L., Raisman‐Vozari, R., et al. (2025) · Neurotoxicity Research · doi:10.1007/s12640-025-00742-6 · Cited by 3
“…DA neurons rescued by OT or DOT were also functional, we first evaluated their ability to accumulate DA through the high affinity DA transport system, which transports the released neurotransmitter from the extra-cellular space into the presynaptic neuron (Vaughan et al. 2013; Cramb et al. 2023 ).”
Ali, S., Ali, S. A., Kumar, M., Jahan, I., & Hak, J. (2025) · Current Pharmaceutical Research · doi:10.63785/cpr.2025.1.1.114 · Cited by 5
“Despite the availability of symptomatic treatments like levodopa, these therapies often lose effectiveness over time and cannot halt disease progression [61].”
Ryu, Y., Park, H., Kim, J.-E., Seo, H.-H., Lee, C., & Kim, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-12104-5 · Cited by 3
“Therefore, astrocytes may participate in striatal dysfunction, which is a pathway underlying the motor deficits in PD 45 .”
Danna, R., Kondle, S., Amar, O., Mabourakh, M., Chen, G., Fadol, W. B., & Mohieldin, A. M. (2025) · Biology · doi:10.3390/biology14121787 · Cited by 2
“This lack of dopamine is understood to be the primary cause of many of the movement disorders [127,128].”
Uric Acid: A Biomarker and Pathogenic Factor of Affective Disorders and Neurodegenerative Diseases
Chu, T., Liu, G., Liu, J., Wu, Y., & Fang, W. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128333916241003180018 · Cited by 2
Neuroprotective effects of chemical constituents from Nicotiana tabacum L. in Parkinson’s disease
Zang, H., Bai, X., Sui, X., Zhai, X.-R., Wang, Y., Yin, Q., Yin, Q.-Y., Hao, X., Wang, Y.-H., Liao, X., et al. (2025) · Natural Products and Bioprospecting · doi:10.1007/s13659-025-00541-8 · Cited by 2
“Parkinson’s disease (PD), a progressive neurodegenerative disorder affecting > 1% of individuals aged over 60 years worldwide [1], is characterized by the selective degeneration of dopaminergic neurons in the substantia nigra pars compacta.”
Dopamine neurotransmission in Parkinson's disease
Cramb, K. M. L., Noor, H., Wade‐Martins, R., & Cragg, S. J. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-21992-4.00012-9 · Cited by 2
Self-citationSingle-cell transcriptomics unveils atrazine's impact on neurons and microglia in C57BL/6 mice
Zhou, Y., Pan, M., Zheng, Z., Wei, J., Sun, T., Ma, Y., & Sun, Y. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.119545 · Cited by 2
Wu, X., Zhang, T., Feng, J., & Park, S. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157758 · Cited by 2
Zhang, Z., Ouyang, X., Xie, C., Zeng, L., Fu, Q., Yan, Q., Wang, T., Wang, X., & Zhao, L. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1740153 · Cited by 2
Bibliometric analysis of the pathogenesis of Parkinson's Disease
Feng, Y., Wang, K., Guo, X., Guo, H., & Gao, X. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156417 · Cited by 2
Kwaśniewska, K., Fic, W., & Polak-Szczybyło, E. (2026) · Nutrients · doi:10.3390/nu18060995 · Cited by 2
Rocha, G. S., Freire, M. A. M., & Brimblecombe, K. R. (2026) · Journal of Neurophysiology · doi:10.1152/jn.00527.2025 · Cited by 2
Danielyan, M., Nebogova, K., Simonyan, R. M., Hovsepyan, A. S., Avetisyan, Z. A., Սիմոնյան, Կ. Վ., Simonyan, G. M., Khachatryan, V., & Karapetyan, K. (2023) · BMC Neuroscience · doi:10.1186/s12868-023-00838-9 · Cited by 2
Pires, R. G., Pereira, C. R., Penedo, T., Papa, J. P., Roder, M., & Barbieri, F. A. (2024) · International Conference on Systems, Signals and Image Processing · doi:10.1109/iwssip62407.2024.10634032 · Cited by 2
“…ganglia is a region of the central nervous system that consists of clusters of nerve cells located in an area called the substantia nigra , which produces a neurotransmitter called dopamine [5], responsible for communication between nerve cells (neurons) in the brain and other parts of the body.”
BackgroundSelf-assembly Pt hollow nanospheres for highly selective and ultrasensitive detection of dopamine
Duan, P., Sun, Q., Xu, Y., Ni, X., & Zheng, J. (2024) · Microchemical Journal · doi:10.1016/j.microc.2024.112023 · Cited by 2
Novel scandium-doped cobalt chromate: Dopamine sensing and superior supercapacitor performance
Nadar, N. R., Deepak, J., Sharma, S., Krushna, B. R. R., Sridhar, C., Ray, S., Vini, R., Nagabhushana, H., Sowjanya, R., & Puneeth, B. (2025) · Materials Science and Engineering B · doi:10.1016/j.mseb.2025.118306 · Cited by 2
Assessment of oxytocin and dopamine for the patients with post trumatic stress disorders
Al-Kufaishi, A. M. A., & Al-Musawi, N. J. T. (2024) · AIP conference proceedings · doi:10.1063/5.0199670 · Cited by 2
Astrocytes mediate the dopaminergic modulation of tonic GABAergic signaling in substantia nigra
Simmons, D. V., Moreno-Ramos, O. A., Raj, D. D. A., Kaganovsky, K., Pamukcu, A., Vrieler, N., Tkatch, T., Xie, Z., de Sousa, A. I. S., Zampese, E., et al. (2026) · Science Advances · doi:10.1126/sciadv.adq8840 · Cited by 2
“The classical model of network dysfunction argues that striatal dopamine depletion is both necessary and sufficient for the emergence of the cardinal motor symptoms of PD ( 60 ).”
Chen, Z., Li, G., Zhou, L., Zhang, L., & Liu, J. (2023) · medRxiv · doi:10.1101/2023.09.19.23295781 · Cited by 2
GBA1 mutations alter neuronal firing and structure, regulating VGLUT2 and CRYAB in dopamine neuronsPreprint
Rodríguez‐Traver, E., Suárez, L. M., Crespo, C., González-Burgos, I., Vecino, R., Jurado-Coronel, J. C., Galán, M., González-González, M., Moratalla, R., & Vicario‐Abejón, C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.05.606574 · Cited by 2
Barcomb, K., Hsiao, J.-H. T., Lemak, J., Zhuang, X., Coutant, B., Yanez, A., Behal, A., Fu, Y., Lerner, T. N., Nakamura, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.17.643840 · Cited by 2
Moroze, E., Zikopoulos, B., & Yazdanbakhsh, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.17.688918 · Cited by 2
Gu, L., Wang, X., Liu, Y., Tang, H., Gu, J., Wang, W., Lu, X., & Lou, M. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673338465241228021705 · Cited by 1
Zhao, X., Zhang, L., Kramer, L., Wang, B., Guan, M., & Ma, Q. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2529772 · Cited by 2
“More widely accepted neurotransmitter markers include serum 5-hydroxytryptamine (5-HT) [52], γ-aminobutyric acid (GABA) [53], norepinephrine((NE) [10] and dopamine [12].”
Liu, J., Yang, P., Wang, Z., Yang, K., Wang, K., Ainivar, K., Chu, K., & Yang, X. (2025) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2025.105983 · Cited by 1
Dzhashiashvili, Y., McBride, J. L., Fabyanic, E. B., Huang, X., Kelly, B. M., Walton-Gibbs, G. D., Vemireddi, V., Wicks, J. R., Nayal, M., Hippen, A. A., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.12.009 · Cited by 1
Iqbal, M. K., Supratik, K., Khan, B., Ahmad, K., Ge, Y., Ai, Y., Shaikh, S., Khalil, M. I., Guo, S., Sui, A., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70364 · Cited by 1
“Motor deficits, a hallmark of PD, arise primarily from the loss of dopaminergic neurons in the substantia nigra and reduced striatal dopamine levels (Cramb et al., 2023).”
Early-life iron exposure disrupts dopaminergic neuron function and neurobehaviour in zebrafish
Nguyen, T. M. N., Naderi, M., Chandrapalan, T., & Kwong, R. W. M. (2026) · NeuroToxicology · doi:10.1016/j.neuro.2026.103437 · Cited by 1
Liu, Y., Ai, Y., Wu, Y., Zhang, Y., Hua, J., Liu, T., Liu, D., Chen, G.-C., Xu, G., & Chen, L.-H. (2026) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2026.2649766 · Cited by 1
“These neurotransmitters play crucial roles in brain function, and their imbalance has been linked to various disorders, including depression, Parkinson’s disease, and epilepsy (Blier and El Mansari 2013; Cramb et al. 2023; Gao et al. 2023; Huang et al. 2024; Tian et al. 2025).”
Galfano, A., McManus, R., Navarrete, W., Chaudhari, S., Bishop, C., & Salvatore, M. F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093923 · Cited by 1
“This new finding suggests that if release capacity was augmented, as previously reported [19,22], it appears that the inherent DA tissue content in striatum ultimately dictates extracellular levels, including release capacity.”
GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation
Li, P., Gao, Y., & (20030), W. L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s613616 · Cited by 2
“62 In PD, dopamine producing neurons in the substantia nigra slowly die off.”
Goldstein, D. S., & Eisenhofer, G. (2026) · Physiological Reviews · doi:10.1152/physrev.00005.2026 · Cited by 3
Emerging mechanisms and targeted therapy of PANoptosis in neurological diseases
Tang, Q., Xu, M., Xiao, X., Cao, J., & Yang, W. (2026) · Reviews in the Neurosciences · doi:10.1515/revneuro-2026-0062 · Cited by 1
“PD is a common neurodegenerative disease primarily a ff ecting middle-aged and elderly people (Cramb et al. 2023).”
Li, A., Wu, Z., Lu, Z., Si, J., 霍佳佳, Yao, M., Huo, X., Shen, C., Niu, C., & Chen, L. (2026) · Frontiers of Optoelectronics · doi:10.2738/foe.2026.0031 · Cited by 1
Subcellular Localization of Dopamine D1 and D2 Receptors in the Mouse Hippocampus
Swope, C., Sommer, G., Smith, R., Milner, T. A., & Platholi, J. (2026) · The Journal of Comparative Neurology · doi:10.1002/cne.70187 · Cited by 1
Resilience mechanisms in Parkinson’s disease: a domain-specific conceptual framework
Ruppert, M. C., van Eimeren, T., Giehl, K., Helmich, R. C. G., Hönig, M. C., Johansson, M. E., Mitterová, K., Rektorová, I., Waldthaler, J., Pedrosa, D. J., et al. (2026) · Brain · doi:10.1093/brain/awag310 · Cited by 1
Liu, F.-W., Zhang, X.-R., Cong, Y.-F., Liu, Y., Zhang, H., & Hou, X. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0143 · Cited by 1
Assembling a multiscale biomedical knowledge graph for explainable drug repurposing in rare diseases
Annadurai, A. A. K., Bhandary, S., Hegde, S. G., & Chatterjee, J. (2025) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-025-00532-2 · Cited by 1
Roshni, J., Sivakumar, M., Janakiraman, V., Ahmad, S. F., Attia, S. M., & Ahmed, S. S. S. J. (2025) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416525500991 · Cited by 1
Unravelling the Role of the Dopamine D1 Receptor in Anhedonia, Asociality, and Avolition
Witt, K. (2023) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.24646128 · Cited by 1
Fine Motor Serious Game Training Improves Gait in Parkinson’s Disease: A Pilot StudyPreprint
Bégel, V., Puyjarinet, F., Gény, C., Cock, V. C. D., Pinto, S., & Bella, S. D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.16.676299 · Cited by 1
“One of them, Rhythm Workers , is a rhythmic game that we developed and validated in PwPD.[ 21,28,31,32] Notably, this form of rhythmic training differs from standard rhythmic auditory cueing, in which the stimulation is typically delivered while patients walk.”
InfluentialCramb, K. M. L., Noor, H., Thomas-Wright, I., Caiazza, M. C., Szunyogh, S., Milošević, I., Beccano-Kelly, D. A., Cragg, S. J., & Wade‐Martins, R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.11.711038 · Cited by 1
Self-citationJamal, M., Tsukamoto, I., Takei, S., Miki, T., Kinoshita, H., & Murase, T. (2024) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2024-2585
“The main pathophysiological characteristic of PD is the depletion of DA in the nigrostriatal system (Blesa & Przedborski, 2014; Grandi et al., 2018; Cramb et al., 2023).”
BackgroundAl-Sabak, D. F. N., Sadeghi, L., & Dehghan, G. (2024) · AIMS Biophysics · doi:10.3934/biophy.2024022
Rodríguez‐Traver, E., Suárez, L. M., Crespo, C., González-Burgos, I., Vecino, R., Jurado-Coronel, J. C., Galán, M., González-González, M., Díaz‐Guerra, E., Moratalla, R., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5434183/v1
Ma, W., Zhao, G., Liu, R., Li, K., Wu, W., Liu, J., He, X., Hou, L., Yu, P., & Mao, L. (2025) · Angewandte Chemie · doi:10.1002/ange.202502163 · Cited by 4
Carecho, R., Raimundo, A., Ávila‐Gálvez, M. Á., Lopes, H., Sequeira, C. O., Pita, C., Pinto, C., Carregosa, D., Marín, A., González‐Sarrías, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.16.670034
Ziętal, K., Blecharz‐Klin, K., Joniec‐Maciejak, I., Piechal, A., Pyrzanowska, J., Machaj, E., Mirowska-Guzel, D. M., & Widy‐Tyszkiewicz, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199726
“Increased serotonin levels in the striatum facilitate the release of dopamine from dopaminergic terminals in the substantia nigra [7,33,35].”
Pan, P., Kumar, N., Khezerlou, E., Cai, J., Caiola, H., Gether, U., & Zhang, H. (2025) · Research Square · doi:10.21203/rs.3.rs-7730224/v1
Ginseng protein improves the subacute Parkinson’s model
Zhao, Y., Xu, N., Liang, L. R., Lian, W., Pang, B., Li, J., Zhang, J., Sun, T., & Zhao, Y. (2025) · Neurological Research · doi:10.1080/01616412.2025.2568034
“Parkinson’s disease (PD) is a common progressive neurodegenerative disease [1].”
Elghareeb, M. M., Elshopakey, G. E., Rezk, S., Ateya, A. I., Elmorsy, E. M., Anwer, H. M., & Marghani, B. H. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115545
Zhang, Y., Lin, D., Yao, X., Dai, F., Wang, Q., & Zhou, B. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.12.007
Lei, T., Li, C., Liu, Y., Cui, Z., Deng, S., Cao, J., Yang, H., & Chen, P. (2024) · Figshare · doi:10.6084/m9.figshare.26738709
PARENTI, G. (2025) · Electronic Theses and Dissertations Repository (University of Pisa)
Yao, X.-R., Liu, Y., Zheng, W., Huang, M., & He, K. (2025) · Advanced Science · doi:10.1002/advs.202513670
Fang, H., Li, P., Gao, Q., Du, S., Gu, J., Liu, X., Peng, B., Bai, H., Zhang, C.-W., Li, L., et al. (2026) · Science China Chemistry · doi:10.1007/s11426-025-2982-3
da Silva, M. L. O. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Torres, R., Kovtun, O., McBride, J. R., Bellocchio, L. G., & Rosenthal, S. J. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00897
Xue, J., Liu, M., Cao, Y., Hao, Z., Wang, Y., Wang, Y., Lu, Y., Fan, W., Zhang, G., & Shi, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-39135-w
Alfaro-Rodríguez, A., González-Maciel, A., Reyes-Long, S., Pérez-Guillé, B., Soriano‐Rosales, R. E., González-Zamora, J. F., Jaime, H. B., & Cortes-Altamirano, J. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052320
Xu, D., Luo, Y., Fu, J., Li, X., Ding, Y., Xiong, F., Wang, J., Lin, L., Yang, H., Liu, J., et al. (2026) · IEEE Sensors Journal · doi:10.1109/jsen.2026.3669014
“As a crucial neurotransmitter, DA plays a pivotal role in neural functions, and its dysregulation is associated with debilitating diseases such as Parkinson’s disease and schizophrenia [7], [8], [9].”
SHKRETA, M. (2026) · Electronic Theses and Dissertations Repository (University of Pisa)
Mo, J., Sun, Z., Xu, G., Zhang, G., Xie, Z., Zhao, J., Heng, G. P., Cong, Z., Leng, L., & Chen, S. (2026) · Molecules · doi:10.3390/molecules31081285
Genetic and Proteomic Investigation of the Smoking-Parkinson’s Disease AssociationPreprint
Shi, M., Gunawan, T., Setzer, M. R., Okashah, N., Liu, Y., Wingo, T. S., Wingo, A. P., Weintraub, D., Schwarzschild, M. A., Rentsch, C. T., et al. (2026) · medRxiv · doi:10.64898/2026.04.17.26351138
Fesenko, Z. S., Volnova, A. B., Efimova, E. V., Sotnikova, T. D., & Gainetdinov, R. R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083656
Chen, Y., Chen, Y., Lin, A., Ding, L., Wang, L., Xia, Z., & Wang, R. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1796614
“Parkinson’s disease (PD) represents a prevalent neurodegenerative disorder among middle-aged and elderly individuals (Ben-Shlomo et al., 2024; Cramb et al., 2023; Simon et al., 2020).”
牛会康, Wang, X., Cao, D., An, J., & Wang, S. (2026) · Materials Research Express · doi:10.1088/2053-1591/ae67e2
The Microbiome-Body Connection: Unraveling the Gut-Brain Axis
Islam, M. M., Mahbub, N. U., & Islam, M. A. (2026) · Springer eBooks · doi:10.1007/978-981-95-7494-0_1 · Cited by 1
Wang, Z.-A., Liu, S. F., Zhao, Z., Liao, X., Yang, L., Zuo, H., 翁少萍, He, J., & Xu, X. (2026) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2026.111457
Connor‐Robson, N., Diviney, T., Alegre‐Abarrategui, J., Roberts, B. M., Brimblecombe, K. R., Bengoa‐Vergniory, N., Waters, H., Cioroch, M., Davies, B. L., Bila, K. O., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.25.727583
Self-citationFei, Y., Hao, M., Liu, J., Dong, Y., Zou, H., Guo, X., An, S., Sang, J., & Xu, T. (2026) · Phytotherapy Research · doi:10.1002/ptr.70392
“…and systemic disruption of cellular homeostasis, including lysosomal dysfunction, ER stress, oxidative damage, and neuroinflammation (Morris et al. 2024; Cramb et al. 2023; Ren et al. 2021; Gitler et al. 2008; Recchia et al. 2004; Vieira and Schapira 2022; Cali et al. 2011; Celardo et al. 2016).”
He, Y., Ou-Yang, K., Yang, H., Wang, L., Li, M., Li, D., & Li, L. (2026) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2026.142640
Krishnan, D., Lakshman, N., Fenwick, E. A., Muthuswamy, K., & Sivasamy, R. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.05.021
Hu, Y., Guo, H., Peng, L., Hui, Y., Kou, J., Zhang, Q., Shi, J., Ren, J., Zhang, J., & Yang, W. Z. (2026) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2026.141582
Pan, P., Kumar, N., Khezerlou, E., Saenz, J., Cai, J., Caiola, H., Nayak, S., Lee, E., Gether, U., Zhang, H., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9695405/v1
Du, W., Zhao, Y., Dong, L., Ma, C., Hu, X., Li, D., Chen, F., & Luo, Y. (2026) · Food Frontiers · doi:10.1002/fft2.70318
Jiang, X., Xu, X. H., Feng, Z., Wang, S., Cai, J., Yu, Y., Sun, Y., Hu, Y., & Sun, Y. (2026) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2026.112012
Hernández-Plata, I., Santiago-Salazar, J., Mendoza-Trejo, M. S., Sánchez-Yépez, J., Garza-Villarreal, E. A., & Rodríguez, V. M. (2026) · NeuroToxicology · doi:10.1016/j.neuro.2026.103500
Metadata
- Authors
- Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R.
- Affiliations
- University of Oxford (GB)
- Oxford Parkinson’s Disease Centre and Department of Physiology, Anatomy and Genetics, University of Oxford , Oxford, OX1 3QU , UK
- Corresponding author
- Cragg, Stephanie J
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-03-02
- Volume
- 146
- Issue
- 8
- Pages
- 3117-3132
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC10393405
- OpenAlex
- W4323036321
- Cited by
- 207
- References
- 157
- Citations by year
- 2026: 63 · 2025: 75 · 2024: 60 · 2023: 8
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Monument Trust Discovery Award from Parkinson’s UK (J-1403)
- MJFF (ASAP-020370)
- Natural Sciences and Engineering Research Council of Canada (PGSD3-517039-2018)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- Parkinson's disease, dopamine release, dopaminergic neurons, striatal dopamine, neurodegeneration, Parkinson's disease model, pathophysiology
- MeSH terms
- Dopamine, Humans, Parkinson Disease, Neurodegenerative Diseases, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.